The effect of curcumin and bromelain in patients with diabetic neuropathy

The effect of curcumin and bromelain on anxiety, stress, depression, quality of life and sleep quality in diabetic neuropathy patients.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191105045340N5

Enrollment

100

Registered

2024-06-22

Start date

2024-06-21

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic neuropathy. Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified

Interventions

Intervention 1: Intervention group: The intervention group consumes 2 capsules of the combined supplement of curcumin and bromelain each day, each capsule containing 150 mg of bromelain equivalent to

Eligibility

Sex/Gender

All

Age

40 Years to 65 Years

Inclusion criteria

Inclusion criteria: Having type 2 diabetes based on the diagnosis of a specialist doctor Diabetic neuropathy in this study will be based on the diagnosis of a specialist doctor and clinical or paraclinical diagnostic criteria. Willingness to cooperate Age 40 to 65 years BMI of people should be in the range of 18.5 to 30 Absence of leg ulcers, visual disturbances and dizziness

Exclusion criteria

Exclusion criteria: Allergy to pineapple Having neurological diseases that cause neuropathy. Taking drugs that interfere with treatment, such as neuroleptics such as SSRIs, antidepressants and anti-stress drugs, and non-steroidal anti-inflammatory drugs Taking anticoagulants

Design outcomes

Primary

Measure	Time frame
Depression. Timepoint: Before the start of the intervention and 8 weeks after taking the supplement. Method of measurement: Questionnaire DASS-21.	—

Secondary

Measure	Time frame
Anxiety. Timepoint: Before the start of the intervention and 8 weeks after taking the supplement. Method of measurement: Questionnaire DASS-21.;Stress. Timepoint: Before the start of the intervention and 8 weeks after taking the supplement. Method of measurement: Questionnaire DASS-21.;Quality of life. Timepoint: Before the start of the intervention and 8 weeks after taking the supplement. Method of measurement: SF-36 questionnaire.;Sleep quality. Timepoint: Before the start of the intervention and 8 weeks after taking the supplement. Method of measurement: Petersburg Questionnaire (PSQI).	—

Measure

Time frame

Anxiety. Timepoint: Before the start of the intervention and 8 weeks after taking the supplement. Method of measurement: Questionnaire DASS-21.;Stress. Timepoint: Before the start of the intervention and 8 weeks after taking the supplement. Method of measurement: Questionnaire DASS-21.;Quality of life. Timepoint: Before the start of the intervention and 8 weeks after taking the supplement. Method of measurement: SF-36 questionnaire.;Sleep quality. Timepoint: Before the start of the intervention and 8 weeks after taking the supplement. Method of measurement: Petersburg Questionnaire (PSQI).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Seyedeh Tayebeh Rahideh

Iran University of Medical Sciences

tayebeh_rahideh@yahoo.com+98 21 8670 1021

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026